Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Entonox versus oxygen for pain during opioid withdrawal detoxification
IRCT20180313039085N4Phase 3Completed
- Sponsor
- Iran University of Medical Sciences
- Start
- Aug 2024
- Modality
- Small Molecules, Implantable Devices → Device-based Delivery → Drug Delivery Systems, Transdermal Patches → Device-based Delivery → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 3, open-label trial of nitrous oxide + oxygen, oxygen and nitrous oxide in substance withdrawal and substance use disorder (SUD) (2 arms), sponsored by Iran University of Medical Sciences. Primary endpoint: Severity of pain experienced as a result of drug withdrawal syndrome. Started Aug 2024; status: completed.
02
Drugs
nitrous oxide + oxygenoxygennitrous oxide
03
Conditions
substance withdrawalsubstance use disorder (SUD)
Beyond the preview
Go deeper on IRCT20180313039085N4.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20180313039085N4.